Autologous and heterologous blood transfusion in head and neck cancer surgery.
OBJECTIVE: To determine if the use of autologous blood ameliorates the increased risk for cancer recurrence that has been associated with perioperative blood transfusion.
DESIGN: Retrospective medical record review.
SETTING: Tertiary care hospital.
PATIENTS: One hundred sixty-five consecutive patients with stages II to IV squamous cell carcinoma of the head and neck treated surgically at a university hospital from January 1, 1989, through December 31, 1994.
MAIN OUTCOME MEASURES: We evaluated the impact of perioperative autologous and heterologous blood transfusion and 10 other variables on recurrence. Univariate and multivariate analyses were used.
RESULTS: Heterologous blood recipients had a 59% recurrence rate, whereas those who had received autologous blood or no transfusion had recurrence rates of 33% and 35%, respectively. The following 4 variables had a statistically significant association with recurrence by multivariate analysis: previous treatment of current malignancy (P
CONCLUSION: Autologous blood products should be used during head and neck cancer surgery if possible when transfusion is necessary.
Published In/Presented At
Moir, M. S., Samy, R. N., Hanasono, M. M., & Terris, D. J. (1999). Autologous and heterologous blood transfusion in head and neck cancer surgery. Archives of otolaryngology--head & neck surgery, 125(8), 864–868. https://doi.org/10.1001/archotol.125.8.864
Medicine and Health Sciences
Department of Surgery